<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847080</url>
  </required_header>
  <id_info>
    <org_study_id>MK-0431</org_study_id>
    <nct_id>NCT00847080</nct_id>
  </id_info>
  <brief_title>Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism</brief_title>
  <official_title>Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sitagliptin is effective in the treatment
      of reactive hypoglycemia by dysinsulinism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Symptomatic reactive hypoglycemia is an abnormal glucose decrease after meal ingestion.
      Patients with this abnormality as an early manifestation of glucose intolerance are at higher
      risk of type 2 diabetes. The pathophysiology of this abnormality appears to be related with
      delayed first phase insulin release. Improvement of first phase insulin secretion and delay
      in gastric emptying induced by sitagliptin phosphate could have favorable effects in patients
      in whom delayed insulin secretion is associated with reactive hypoglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement assessed by a validated questionnaire</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose, insulin, GLP1, GIP</measure>
    <time_frame>First and last evaluations</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Reactive Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin phosphate</intervention_name>
    <description>Sitagliptin phosphate 100 mg per day per 2 weeks</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tablet per day per 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and biochemical diagnosis of prediabetic reactive hypoglycemia

          -  Must be able to swallow tablet

          -  Negative pregnancy test (when appropriate)

        Exclusion Criteria:

          -  Renal insufficiency

          -  Hepatic insufficiency

          -  Diabetes (any type)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J Gomez-Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.innsz.mx/opencms/contenido/english.html</url>
    <description>Click here for information of the study location</description>
  </link>
  <link>
    <url>http://www.msd.com.mx</url>
    <description>Click here for information of study sponsor in spanish</description>
  </link>
  <link>
    <url>http://www.merck.com/</url>
    <description>Click here for information of study sponsor in english</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>April 22, 2011</last_update_submitted>
  <last_update_submitted_qc>April 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Francisco J Gomez-Perez</name_title>
    <organization>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</organization>
  </responsible_party>
  <keyword>Reactive hypoglycemia</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Incretins</keyword>
  <keyword>Prediabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

